16:48 EDT Spruce Biosciences (SPRB) down 13% at $60.50 after equity offering announcement
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences announces common stock offering, no amount given
- Biotech Alert: Searches spiking for these stocks today
- Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline
- Clear Regulatory Path and Strong Cash Position Underpin Buy Rating on Spruce Biosciences and Tralesinidase Alfa
- Spruce Biosciences price target lowered to $170 from $180 at Citizens